Colgate-Palmolive Valuation
Is CL * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CL * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CL * (MX$1513.1) is trading below our estimate of fair value (MX$1604.22)
Significantly Below Fair Value: CL * is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CL *?
Other financial metrics that can be useful for relative valuation.
What is CL *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$73.05b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 4.2x |
Enterprise Value/EBITDA | 18x |
PEG Ratio | 3.2x |
Price to Earnings Ratio vs Peers
How does CL *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 20.4x | ||
KIMBER A Kimberly-Clark de México S. A. B. de C. V | 15x | 5.8% | Mex$110.7b |
KMB Kimberly-Clark | 24.9x | 9.6% | US$45.9b |
RKT Reckitt Benckiser Group | 18.8x | 11.0% | UK£30.7b |
HEN3 Henkel KGaA | 23.1x | 9.8% | €28.7b |
CL * Colgate-Palmolive | 31.9x | 10.0% | Mex$73.0b |
Price-To-Earnings vs Peers: CL * is expensive based on its Price-To-Earnings Ratio (31.9x) compared to the peer average (20.5x).
Price to Earnings Ratio vs Industry
How does CL *'s PE Ratio compare vs other companies in the Global Household Products Industry?
Price-To-Earnings vs Industry: CL * is expensive based on its Price-To-Earnings Ratio (31.9x) compared to the Global Household Products industry average (18.6x).
Price to Earnings Ratio vs Fair Ratio
What is CL *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 31.9x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CL *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$1,513.10 | Mex$1,576.74 +4.2% | 5.8% | Mex$1,763.20 | Mex$1,386.59 | n/a | 21 |
Apr ’25 | n/a | Mex$1,506.82 0% | 5.0% | Mex$1,614.57 | Mex$1,362.29 | n/a | 21 |
Mar ’25 | Mex$1,478.50 | Mex$1,521.52 +2.9% | 5.5% | Mex$1,633.79 | Mex$1,310.43 | n/a | 21 |
Feb ’25 | Mex$1,462.00 | Mex$1,531.14 +4.7% | 5.3% | Mex$1,652.04 | Mex$1,325.07 | n/a | 21 |
Jan ’25 | Mex$1,343.27 | Mex$1,427.83 +6.3% | 6.6% | Mex$1,545.11 | Mex$1,287.59 | n/a | 19 |
Dec ’24 | Mex$1,324.90 | Mex$1,417.16 +7.0% | 6.1% | Mex$1,558.22 | Mex$1,298.52 | n/a | 19 |
Nov ’24 | Mex$1,350.20 | Mex$1,467.23 +8.7% | 5.9% | Mex$1,622.68 | Mex$1,352.24 | n/a | 18 |
Oct ’24 | Mex$1,240.00 | Mex$1,480.78 +19.4% | 7.7% | Mex$1,718.11 | Mex$1,192.16 | n/a | 19 |
Sep ’24 | Mex$1,250.00 | Mex$1,455.15 +16.4% | 8.1% | Mex$1,680.12 | Mex$1,165.80 | n/a | 18 |
Aug ’24 | Mex$1,287.00 | Mex$1,419.66 +10.3% | 8.1% | Mex$1,640.95 | Mex$1,121.87 | n/a | 19 |
Jul ’24 | n/a | Mex$1,457.28 0% | 7.4% | Mex$1,642.75 | Mex$1,146.50 | n/a | 18 |
Jun ’24 | Mex$1,312.22 | Mex$1,494.81 +13.9% | 7.2% | Mex$1,688.36 | Mex$1,178.34 | n/a | 19 |
May ’24 | n/a | Mex$1,515.86 0% | 7.3% | Mex$1,721.15 | Mex$1,201.22 | n/a | 20 |
Apr ’24 | Mex$1,360.77 | Mex$1,464.30 +7.6% | 5.9% | Mex$1,628.92 | Mex$1,212.64 | n/a | 21 |
Mar ’24 | Mex$1,310.00 | Mex$1,488.46 +13.6% | 5.9% | Mex$1,653.85 | Mex$1,231.20 | Mex$1,478.50 | 21 |
Feb ’24 | Mex$1,352.00 | Mex$1,515.61 +12.1% | 5.9% | Mex$1,689.23 | Mex$1,257.54 | Mex$1,462.00 | 20 |
Jan ’24 | n/a | Mex$1,585.76 0% | 5.8% | Mex$1,719.15 | Mex$1,304.18 | Mex$1,343.27 | 20 |
Dec ’23 | Mex$1,487.60 | Mex$1,551.27 +4.3% | 5.6% | Mex$1,645.14 | Mex$1,277.40 | Mex$1,324.90 | 20 |
Nov ’23 | Mex$1,446.00 | Mex$1,589.11 +9.9% | 5.5% | Mex$1,684.22 | Mex$1,307.75 | Mex$1,350.20 | 20 |
Oct ’23 | n/a | Mex$1,640.44 0% | 7.0% | Mex$1,818.15 | Mex$1,358.62 | Mex$1,240.00 | 19 |
Sep ’23 | Mex$1,593.00 | Mex$1,683.47 +5.7% | 7.0% | Mex$1,862.26 | Mex$1,391.58 | Mex$1,250.00 | 19 |
Aug ’23 | n/a | Mex$1,674.95 0% | 7.2% | Mex$1,854.02 | Mex$1,365.05 | Mex$1,287.00 | 19 |
Jul ’23 | n/a | Mex$1,687.27 0% | 7.1% | Mex$1,875.89 | Mex$1,463.61 | n/a | 20 |
Jun ’23 | Mex$1,561.70 | Mex$1,602.59 +2.6% | 7.0% | Mex$1,783.66 | Mex$1,391.65 | Mex$1,312.22 | 21 |
May ’23 | Mex$1,630.00 | Mex$1,725.22 +5.8% | 7.1% | Mex$1,938.83 | Mex$1,449.02 | n/a | 21 |
Apr ’23 | Mex$1,507.00 | Mex$1,713.36 +13.7% | 7.1% | Mex$1,889.64 | Mex$1,491.82 | Mex$1,360.77 | 21 |
Analyst Forecast: Target price is less than 20% higher than the current share price.